Selected article for: "binding affinity and high affinity"
Author: Hong-Yan Zhang; Lin-Wei Wang; Yuan-Yuan Chen; Xiao-Kun Shen; Qun Wang; You-Qin Yan; Yi Yu; Qiuji Wu; Xinghuan Wang; Ya-Hua Zhong; Melvin Chua Lee Kiang; Cong-Hua Xie
Title: A Multicentre Study of 2019 Novel Coronavirus Disease Outcomes of Cancer Patients in Wuhan, China
  • Document date: 2020_3_26
    • ID: 8rxjju0t_44
    Snippet: Particularly, about 70% of patients with concurrent hypertension were severe, accounting for the majority of the severe patients in our study. Recent studies suggested that angiotensin-converting enzyme-2 (ACE2) could be the host receptor for SARS-CoV-2 with high binding affinity. 18 19 Besides, the expression of ACE2 in tumour tissues could be higher than adjacent tissues and there is expression heterogeneity across different cancer types. 20 In.....
    Document: Particularly, about 70% of patients with concurrent hypertension were severe, accounting for the majority of the severe patients in our study. Recent studies suggested that angiotensin-converting enzyme-2 (ACE2) could be the host receptor for SARS-CoV-2 with high binding affinity. 18 19 Besides, the expression of ACE2 in tumour tissues could be higher than adjacent tissues and there is expression heterogeneity across different cancer types. 20 In the clinical courses of cancer patients with COVID-19, lymphocytopenia was observed, especially in severe patients/non-survivors, which might result from targeted damages by SARS-CoV viral particles. 21 Our findings were consistent with previous studies on COVID -19, 4, 15 indicating that lymphocytopenia reflects the severity of COVID-19 in a way.

    Search related documents:
    Co phrase search for related documents
    • adjacent tissue and cancer type: 1, 2
    • angiotensin convert and host receptor: 1, 2
    • binding affinity and cancer patient: 1, 2
    • binding affinity and cancer type: 1
    • binding affinity and high binding affinity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • binding affinity and host receptor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • binding affinity and previous study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • binding affinity and recent study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • cancer patient and clinical course: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • cancer patient and expression heterogeneity: 1
    • cancer patient and high binding affinity: 1, 2
    • cancer patient and previous study: 1
    • cancer patient and recent study: 1
    • cancer patient clinical course and clinical course: 1
    • cancer type and different cancer type: 1, 2, 3, 4
    • cancer type and host receptor: 1
    • cancer type and non survivor: 1
    • cancer type and previous study: 1, 2, 3, 4, 5
    • cancer type and recent study: 1, 2, 3, 4, 5